Taysha Gene Therapies (TSHA) Invested Capital (2020 - 2023)

Taysha Gene Therapies (TSHA) reported Invested Capital of $40.0 million for Q3 2023, up 66566.67% sequentially from $60000.0 in Q3 2020.

Taysha Gene Therapies (TSHA) Invested Capital (2020 - 2023) Analysis & Trends

Taysha Gene Therapies (TSHA) has 2 years of Invested Capital data on file, last reported at $40.0 million in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.96 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 116.14 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Taysha Gene Therapies 2.14 Bn 2.14 Bn - -

Historic Data

Download Data
DateValue
Sep 30, 2023 40.00 Mn
Sep 30, 2020 60,000.00